NCT02950805 - A Study to Assess the Effect of AZD5634 on Mucociliary Clearance, Safety, Tolerability and Pharmacokinetic Parameters in Patients With Cystic Fibrosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 30, 2017

Primary Completion Date

April 12, 2018

Study Completion Date

April 12, 2018

Conditions

Pulmonary/Respiratory Diseases

Interventions

DRUG

Placebo

Subjects will receive a placebo in either period 1 or period 2 by inhalation.

DRUG

AZD5634

Subjects will receive a single tentative dose of 625 μg of AZD5634 in either period 1 or period 2 by inhalation.

Trial Locations (3)

Research Site, Baltimore

Research Site, Chapel Hill

Research Site, Birmingham